Format

Send to

Choose Destination
Thorax. 2016 Feb;71(2):161-70. doi: 10.1136/thoraxjnl-2015-207140. Epub 2015 Dec 8.

UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening.

Author information

1
Roy Castle Lung Cancer Research Programme, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
2
Queen Mary University of London, London, UK.
3
Department of Respiratory Medicine, Nottingham University Hospitals, Nottingham, UK.
4
School of Economics, University of Nottingham, Nottingham, UK.
5
Royal Brompton and Harefield NHS Foundation Trust, London, UK.
6
Cardiff University School of Medicine, Cardiff, UK.
7
University of Cambridge, Cambridge Biomedical Research Centre, Cambridge, UK.
8
Department of Pathology, Royal Liverpool and Broadgreen University Hospital Trust, Liverpool, UK.
9
Liverpool Heart and Chest Hospital, NHS Foundation Trust, Liverpool UK.
10
Lung Cancer Patient Advocate, Liverpool, UK.
11
Department of Pathology, Aberdeen Royal Infirmary, Aberdeen, UK.
12
Guy's and St Thomas' NHS Foundation Trust, London, UK.
13
Medical Research Council Clinical Trials Unit at UCL, London, UK.
14
Department of Histopathology, Papworth Hospital NHS Foundation Trust, Cambridge, UK.
15
Center for Population Health Sciences, University of Edinburgh, Edinburgh, UK.

Abstract

BACKGROUND:

Lung cancer screening using low-dose CT (LDCT) was shown to reduce lung cancer mortality by 20% in the National Lung Screening Trial.

METHODS:

The pilot UK Lung Cancer Screening (UKLS) is a randomised controlled trial of LDCT screening for lung cancer versus usual care. A population-based questionnaire was used to identify high-risk individuals. CT screen-detected nodules were managed by a pre-specified protocol. Cost effectiveness was modelled with reference to the National Lung Cancer Screening Trial mortality reduction.

RESULTS:

247 354 individuals aged 50-75 years were approached; 30.7% expressed an interest, 8729 (11.5%) were eligible and 4055 were randomised, 2028 into the CT arm (1994 underwent a CT). Forty-two participants (2.1%) had confirmed lung cancer, 34 (1.7%) at baseline and 8 (0.4%) at the 12-month scan. 28/42 (66.7%) had stage I disease, 36/42 (85.7%) had stage I or II disease. 35/42 (83.3%) had surgical resection. 536 subjects had nodules greater than 50 mm(3) or 5 mm diameter and 41/536 were found to have lung cancer. One further cancer was detected by follow-up of nodules between 15 and 50 mm(3) at 12 months. The baseline estimate for the incremental cost-effectiveness ratio of once-only CT screening, under the UKLS protocol, was £8466 per quality adjusted life year gained (CI £5542 to £12 569).

CONCLUSIONS:

The UKLS pilot trial demonstrated that it is possible to detect lung cancer at an early stage and deliver potentially curative treatment in over 80% of cases. Health economic analysis suggests that the intervention would be cost effective-this needs to be confirmed using data on observed lung cancer mortality reduction.

TRIAL REGISTRATION:

ISRCTN 78513845.

KEYWORDS:

Imaging/CT MRI etc; Lung Cancer

PMID:
26645413
PMCID:
PMC4752629
DOI:
10.1136/thoraxjnl-2015-207140
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center